Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Voyager Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Voyager Therapeutics, Inc.’s stock price such as:

• Voyager Therapeutics, Inc.’s current stock price and volume
• Why Voyager Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for VYGR from analysts
• VYGR’s stock price momentum as measured by its relative strength

About Voyager Therapeutics, Inc. (VYGR)

Before we jump into Voyager Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich’s ataxia; and GBA1 gene replacement program to treat parkinson’s disease. In addition, it provides research program for the treatment of Huntington’s disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Want to learn more about Voyager Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Voyager Therapeutics, Inc..

Voyager Therapeutics, Inc.’s Stock Price as of Market Close

As of June 11, 2025, 1:02 PM, CST, Voyager Therapeutics, Inc.’s stock price was $3.505.

Voyager Therapeutics, Inc. is up 1.3% from its previous closing price of $3.460.

During the last market session, Voyager Therapeutics, Inc.’s stock traded between $3.430 and $3.630. Currently, there are approximately 58.35 million shares outstanding for Voyager Therapeutics, Inc..

Voyager Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Voyager Therapeutics, Inc. Stock Price History

Voyager Therapeutics, Inc.’s (VYGR) price is currently up 27.92% so far this month.

During the month of June, Voyager Therapeutics, Inc.’s stock price has reached a high of $3.730 and a low of $3.145.

Over the last year, Voyager Therapeutics, Inc. has hit prices as high as $9.550 and as low as $2.645. Year to date, Voyager Therapeutics, Inc.’s stock is down 38.18%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Voyager Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there were 6 analysts who downgraded Voyager Therapeutics, Inc.’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Voyager Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Voyager Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Voyager Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Voyager Therapeutics, Inc. (VYGR) by visiting AAII Stock Evaluator.

Relative Price Strength of Voyager Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, Voyager Therapeutics, Inc. has a weighted four-quarter relative price strength of -21.60%, which translates to a Momentum Score of 8 and is considered to be Very Weak.

Want to learn more about how Voyager Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Voyager Therapeutics, Inc. Stock Price: Bottom Line

As of June 11, 2025, Voyager Therapeutics, Inc.’s stock price is $3.505, which is up 1.3% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Voyager Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.